CEO Letter to Shareholders: 2015 Results Expand Therapy Options for Concussion

Dear Shareholders:

Concussion and traumatic brain injury (TBI) are significant health risks that lack modern therapeutic approaches beyond physical therapy and rehabilitation.  The TBI incidence in the US is 1.5 to 1.7 million new cases per year and is estimated to cost $75 billion per year in the US only.  Concussion is a growing issue within […]

November 5th, 2015|

Vitro Biopharma Launches New Bioanalytical Services and Novel Stem Cell-derived Renal & Neural Cells

Golden, Colorado—September  22, 2015 —Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced expansion of its product/service offerings to include biomarker profiling services and stem cell derived neuronal and renal cells. Vitro Biopharma’s new services include simultaneous determination of several molecules through multi-plexed assays.  The cells of our bodies communicate with each other through the […]

September 25th, 2015|

Vitro Biopharma Announces Advancement of its Traumatic Brain Injury Clinical Trial & a Favorable Ruling from the FDA

Golden, Colorado—September 2, 2015 —Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced advances in clinical applications of its products and a favorable ruling by the FDA regarding this trial.  The Company’s phase I clinical trial consists of combining two previously FDA-approved drugs in a novel manner to treat TBI including concussion by regeneration of […]

September 3rd, 2015|

Vitro Biopharma Launches MSC-derived Cardiac and Neural Cells for Pre-clinical Toxicology Testing

Golden, Colorado—June 2, 2015 —Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced the commercial launch of cardiac and neural cells that are differentiated from human MSCs.  Our new products include cardiomyocytes, alpha motor neurons and neural stem cells.  In support of this commercial launch, we have also launched an improved and updated website featuring […]

June 8th, 2015|

Vitro Biopharma Expands Capacity to Meet Increased Demand for MSC-Gro™ Stem Cell Culture Media

Golden, Colorado—April 29, 2015 —Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced expansion of manufacturing capacity based on a recent orders for bulk quantities of  its MSC-Gro™ Brand of stem cell growth media. Increased demand comes from sales to stem cell researchers and a new customer who recently qualified our media for use in […]

April 29th, 2015|

Vitro Biopharma Announces Advances in Clinical Application of Stem Cell Therapy for Neurological Conditions

Golden, Colorado—February 18, 2015 —Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced advances in its stem cell products and services that enhance opportunities to expand clinical studies of stem therapy of neurological conditions.  We have previously announced a pre-clinical study of our human MSCs for treatment of stroke in animals that showed near reversal […]

February 18th, 2015|

Stem Cell Therapy of Stroke: Current Research Support and Clinical Studies

Adult stem cell therapy is a common FDA-approved procedure for treatment of blood disorders including leukemia, lymphoma and autoimmune diseases.  Cell therapy using other types of adult stem cells including mesenchymal stem cells (MSCs), neural stem cells (NSCs) and muscle stem cells (Satellite cells) is supported by research findings and proof-of-principle clinical trials but this […]

February 17th, 2015|

Alternatives to Stem Cell Transplants Supported by Key Medical Breakthroughs of 2014

Golden, Colorado—January 13, 2015 —Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced the growing scientific support for use of stem cells that reside within the body for therapeutic and performance enhancement.  A key medical advance of 2014 was research published by scientists at Stanford University and Harvard University regarding mechanisms underlying “parabiosis”, the well-known […]

January 13th, 2015|

Vitro Biopharma Announces CEO Letter to Shareholders: 2014 Revenue Growth Supports 2015 Expansion of Stem Cell Clinical Trials & Revenue

Golden, Colorado—November 19, 2014—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced its CEO letter to its shareholders including discussion of 2014 results and plans for 2015 including advances towards expanded clinical trials of its novel stem cell activation technology.

Dear Shareholders,

In 2014 we achieved:

Nearly 4-fold revenue growth due to addition of CRO services and support […]

November 19th, 2014|

Vitro Biopharma Launches new Cell Lines to Bolster Revenue Growth

Golden, Colorado—October 29, 2014—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma announced the launch of several new products especially cell lines including stem cells and CAFs–cancer-associated fibroblasts targeting research and clinical development markets in cancer and regenerative medicine.  Our new stem cells include neural stem cells (NSCs) derived from MSCs together with an advanced growth […]

October 29th, 2014|